RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

RecoverPC: A Phase 2 Study of RElugolix versus GnRH agonist quality of life (QOL) and testosterone reCOVERy in men with Prostate Cancer (DF/HCC 22-599)

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label.

The names of the study drugs involved in this study are:

  • Leuprolide (type of ADT)
  • Relugolix (type of ADT)

Learn More

 


Contact

Clinical Trials Office at [email protected] or (203) 358-8879.

Principal Investigator(s)

Anthony Gulati, MD

Sponsor(s)

Dana-Farber Cancer Institute

Location

Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.